Gilead Sciences agreed to acquire Arcellx in a cash deal valuing the CAR‑T developer at about $7.8 billion. The deal consolidates Gilead’s stake in anito‑cel, a BCMA‑directed CAR‑T therapy that is under FDA review for relapsed or refractory multiple myeloma. Gilead said the buyout accelerates its plans to commercialize anito‑cel and position its cell‑therapy unit to compete with Johnson & Johnson and Legend Biotech’s approved BCMA product. Under the terms, Arcellx shareholders receive $115 per share in cash with an additional potential $5 per share tied to future sales milestones. Gilead’s statement cited conviction in anito‑cel’s potential and the transaction follows an existing co‑development and co‑marketing collaboration between the companies. The FDA is currently reviewing anito‑cel’s filing; the acquisition layers corporate control over the program as regulators assess the therapy’s risk‑benefit profile. Analysts flagged the deal as a strategic bid to regain momentum in Gilead’s cell‑therapy franchise after several quarters of underperformance. The buyout transfers full commercial and R&D responsibility for anito‑cel to Gilead, removing partner coordination but adding integration and launch risk ahead of potential approval and market entry.